Urinary Concentrations of Four Parabens in the U.S. Population: NHANES 2005–2006 by Calafat, Antonia M. et al.
Environmental Health Perspectives  •  v o l u m e  118 | n u m b e r 5 | May  2010  679
Research
Parabens are esters of p-hydroxybenzoic acid. 
They are used as antimicrobial preservatives, 
especially against molds and yeast, in cos-
metics, pharmaceuticals, and food and bever-
age processing (Andersen 2008; Elder 1984). 
Parabens are popular preservatives because of 
their low toxicity and cost, their broad inert-
ness, and their worldwide regulatory accep-
tance (Soni et al. 2005). Methyl paraben 
(MP) and propyl paraben (PP) are two of the 
most used parabens (Andersen 2008).
Parabens are not mutagenic (Elder 1984), 
but their potential estrogenic activity—which 
is orders of magnitude lower than that of estro-
gen (Andersen 2008; Golden et al. 2005)—has 
raised some concerns. The presence of para-
bens in human breast tumors (Darbre et al. 
2004) triggered a debate about their use in 
cosmetics, particularly in underarm deodorants 
and antiperspirants, and the incidence of breast 
cancer (Darbre 2006; Darbre and Harvey 
2008; Golden et al. 2005; Harvey and Darbre 
2004). However, the Scientific Committee 
on Consumer Products (SCCP) of the 
European Commission concluded that there 
was no evidence that using paraben-containing 
underarm cosmetics increased the demon-
strable risk of breast cancer (SCCP 2005). In 
2003, the Cosmetic Ingredient Review (CIR) 
expert panel, part of a program established 
by the Cosmetics, Toiletry, and Fragrance 
Association, with support from the U.S. Food 
and Drug Administration and the Consumer 
Federation of America, decided to reevaluate 
the safety of parabens (Bergfeld et al. 2005) 
and to assess their link to endocrine disruption. 
In 2006, the CIR panel concluded that methyl, 
ethyl, propyl, isopropyl, butyl, isobutyl, and 
benzyl parabens are safe as cosmetic ingredi-
ents in the practices of use and use concentra-
tions (up to 0.4% if used alone, up to 0.8% in 
mixtures) (Andersen 2008). Nonetheless, the 
National Institute of Environmental Health 
Sciences has recommended butyl paraben (BP) 
for toxicologic evaluation because of its wide-
spread use, its potential reproductive toxic-
ity, and the lack of adequate toxicologic data 
(National Toxicology Program 2004, 2006). 
Furthermore, SCCP recently concluded that 
the safety assessment of PP and BP could not 
yet be finalized on the basis of available data 
(SCCP 2008).
Exposure to parabens may occur through 
inhalation, dermal contact, and ingestion (El 
Hussein et al. 2007; Soni et al. 2005), and 
metabolism may differ, depending upon the 
exposure route (Bando et al. 1997; Soni et al. 
2005). Also, metabolism and uptake from 
human skin may be lower than in other spe-
cies (Harville et al. 2007; Jewell et al. 2007a; 
Prusakiewicz et al. 2006), and interindi-
vidual differences among humans in dermal 
metabolic capacity exist (Jewell et al. 2007b). 
Parabens can be hydrolyzed to p-hydroxy-
benzoic acid, which can be conjugated before 
urinary excretion (Kiwada et al. 1979, 1980), 
but they can also be excreted as intact esters 
(Ye et al. 2006a). The fraction of the parabens 
excreted in the urine as the parent paraben (free 
or conjugated) versus the fraction excreted as 
p-hydroxybenzoic acid is unknown. In humans, 
p-hydroxybenzoic acid, a nonspecific metabo-
lite of all parabens, and its conjugates in urine 
are not optimal biomarkers of exposure to 
parabens, known to have quite different bio-
activities. By contrast, the concentrations of 
total (free plus conjugated) urinary species of 
the parent parabens can be used as valid human 
exposure bio  markers (Ye et al. 2006a).
Our evaluation of the urinary concentra-
tions of parabens among 100 adults with no 
known occupational exposure to the com-
pounds showed widespread exposure to these 
chemicals (Ye et al. 2006a). Here we report 
the first nationally representative data on the 
total concentrations of four parabens in urine 
among those in the U.S. general population 
≥ 6 years of age, stratified by age group, sex, 
and race/ethnicity.
Methods
Since 1999, the Centers for Disease Control 
and Prevention (CDC) has conducted annu-
ally the National Health and Nutrition 
Examination Survey (NHANES) to meas-
ure the health and nutritional status of the 
civilian noninstitutionalized U.S. population 
≥ 2 months of age (CDC 2009b). NHANES 
includes household interviews, standardized 
physical examinations, and collection of med-
ical histories and biologic specimens. Some of 
these specimens are used to assess exposure to 
environmental chemicals (CDC 2009b). For 
this study, 2,548 urine specimens were col-
lected from a one-third subset of participants 
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≥ 6 years of age. The representative design of 
the survey was maintained because the subset 
was random. The National Centers for Health 
Statistics Institutional Review Board reviewed 
and approved the study protocol. All partici-
pants gave informed written consent; parents 
or guardians provided consent for participants 
< 18 years of age.
Participants provided one spot urine 
sample during one of three daily examina-
tion sessions. The samples were shipped 
on dry ice to CDC’s National Center for 
Environmental Health and stored at tem-
peratures below –20°C until analyzed. We 
measured the concentrations of total para-
bens, described in detail elsewhere (Ye et al. 
2006b). We first hydrolyzed the conjugated 
species of parabens in 100 µL urine by use of 
β-glucuronidase/sulfatase (Helix pomatia, H1; 
Sigma Aldrich Laboratories, Inc., St. Louis, 
MO). The parabens were preconcentrated by 
online solid-phase extraction, separated from 
other urine components by reversed-phase 
high-performance liquid chromatography, and 
detected by atmospheric pressure chemical 
ionization–isotope dilution/tandem mass spec-
trometry with peak focusing (Ye et al. 2006b). 
The limits of detection (LODs) in synthetic 
urine, calculated as 3S0, where S0 is the stan-
dard deviation as the concentration approaches 
zero (Taylor 1987), were 1.0 µg/L [MP, ethyl 
paraben (EP)] and 0.2 µg/L (PP, BP). We 
prepared low-concentration (2.2–9.0 µg/L) 
and high-concentration (10.5–53.8 µg/L) 
quality control materials (QCLs and QCHs, 
respectively) with pooled human urine that 
was analyzed with standards, reagent blanks, 
and NHANES samples. The precision of mea-
surements, expressed as the relative standard 
deviation of 55–66 meas  ures, depending on 
the analyte, was 5.8–12.1% for QCLs and 
4.4–5.6% for QCHs.
We used SAS (version 9.1.3; SAS Institute 
Inc., Cary, NC) and SUDAAN (version 10; 
Research Triangle Institute, Research Triangle 
Park, NC) to perform statistical analyses. 
SUDAAN calculates variance estimates after 
incorporating the sample population weights, 
used to produce estimates that are representa-
tive of the U.S. population, which account 
for nonresponse rates, unequal selection prob-
abilities, and planned oversampling of cer-
tain subgroups resulting from the complex 
multistage probability design of NHANES. 
We stratified age, reported in years at the 
last birthday, in four groups (6–11, 12–19, 
20–59, and ≥ 60 years). On the basis of self-
reported data, we categorized race/ethnicity as 
non-Hispanic black, non-Hispanic white, and 
Mexican American. Participants not defined 
by these racial/ethnic categories were included 
only in the total population estimate. For 
each age, sex, and race/ethnic group, we cal-
culated the geometric means (if the overall 
weighted frequency of detection was > 60%) 
and distribution percentiles for both volume-
based (micrograms per liter) and creatinine-
corrected (micrograms per gram creatinine) 
concentrations. For concentrations below 
the LOD, we used a value equal to the LOD 
divided by the square root of 2 in univariate 
and multivariate analyses, as recommended 
for examining NHANES data (CDC 2009a).
We used analysis of covariance to exam-
ine whether several variables, selected on the 
basis of statistical, demographic, and bio-
logical considerations, were associated with 
the log-transformed urine concentrations of 
MP and PP. We considered age (continu-
ous), sex, race/ethnicity, creatinine concentra-
tion, household income (described below), 
and examination session (i.e., morning, after-
noon, evening). On the basis of question-
naire responses, annual household income was 
Table 1. Geometric means and selected percentiles (95% CIs) of MP concentrations in urine for the U.S. population ≥ 6 years of age: NHANES 2005–2006.
Variable Geometric mean
Percentile Sample 
size 10th 25th 50th 75th 90th 95th
All
µg/L 56.4 (46.9–67.9) 5.60 (4.70–6.90) 13.4 (10.6–17.6) 63.5 (47.9–74.5) 216 (168–282) 560 (432–777) 974 (827–1,110) 2,548
µg/g creatinine 55.0 (46.8–64.6) 5.38 (4.55–6.10) 12.9 (11.0–15.9) 58.8 (47.0–73.4) 221 (170–264) 527 (426–685) 902 (753–995) 2,548
Age group (years)
6–11
µg/L 33.5 (25.6–43.8) 5.20 (4.60–5.60) 9.60 (7.80–13.8) 25.0 (19.4–35.3) 86.7 (61.5–153) 289 (238–868) 1,560 (389–2,090) 356
µg/g creatinine 36.8 (27.9–48.7) 5.79 (3.97–7.80) 10.5 (7.62–17.4) 26.9 (21.0–36.6) 108 (55.9–164) 259 (195–753) 1,540 (313–2,510) 356
12–19
µg/L 53.8 (43.9–66.0) 6.40 (5.20–7.20) 14.2 (11.9–18.7) 53.5 (39.4–65.7) 192 (163–264) 491 (380–720) 901 (571–1,210) 702
µg/g creatinine 40.1 (33.7–47.8) 4.54 (3.75–5.43) 10.5 (8.17–12.5) 41.7 (31.5–56.3) 160 (129–178) 362 (280–428) 549 (434–656) 702
20–59
µg/L 61.0 (47.8–78.0) 5.70 (4.10–7.30) 15.3 (10.7–21.1) 71.3 (57.3–92.1) 221 (168–322) 557 (412–814) 949 (742–1,120) 1,040
µg/g creatinine 58.6 (47.9–71.7) 5.39 (4.03–6.84) 14.2 (11.8–18.4) 65.9 (48.5–89.7) 242 (170–295) 561 (416–733) 910 (706–1,010) 1,040
≥ 60
µg/L 58.0 (49.3–68.2) 6.10 (4.70–7.70) 11.6 (8.90–14.7) 59.8 (42.0–90.0) 243 (177–347) 661 (490–877) 1,040 (877–1,200) 450
µg/g creatinine 67.5 (55.1–82.7) 5.64 (4.61–7.27) 14.2 (10.3–18.5) 86.4 (58.6–109) 326 (221–397) 709 (508–824) 988 (799–1,550) 450
Sex
Female
µg/L 104 (80.8–135) 9.10 (6.20–14.1) 35.4 (22.1–48.3) 137 (93.0–168) 356 (279–427) 842 (660–974) 1,110 (956–1,335) 1,278
µg/g creatinine 123 (99.3–152) 12.9 (9.03–17.7) 43.2 (29.1–61.6) 147 (111–196) 377 (319–445) 788 (676–910) 1,050 (937–1,290) 1,278
Male
µg/L 29.8 (24.8–35.8) 4.10 (2.90–5.60) 8.30 (7.20–10.1) 23.7 (19.4–29.4) 97.6 (78.1–121) 299 (229–355) 491 (385–743) 1,270
µg/g creatinine 23.9 (20.6–27.8) 3.73 (2.95–4.57) 7.48 (6.16–8.40) 21.1 (17.4–25.3) 72.1 (58.0–89.5) 209 (160–260) 368 (262–498) 1,270
Race/ethnicitya
Mexican American
µg/L 78.2 (61.0–100) 8.40 (5.30–11.3) 21.8 (16.1–30.1) 86.3 (64.7–121) 301 (233–349) 742 (474–896) 1,100 (896–1,170) 637
µg/g creatinine  70.3 (57.1–86.7) 7.31 (4.88–10.2) 21.0 (13.6–27.7) 85.8 (67.2–106) 249 (191–303) 515 (431–656) 870 (656–1,080) 637
Non-Hispanic black
µg/L 174 (133–229) 16.0 (12.7–20.4) 54.2 (31.4–91.6) 216 (150–306) 616 (465–789) 1,180 (1,010–1,480) 1,690 (1,210–2,880) 678
µg/g creatinine  122 (93.0–161) 12.2 (8.30–17.0) 42.4 (24.5–71.1) 161 (98.2–225) 377 (334–462) 792 (581–1,100) 1,220 (916–1,590) 678
Non-Hispanic white
µg/L 43.8 (36.7–52.3) 5.00 (3.70–6.20) 10.7 (8.60–13.6) 44.3 (36.7–58.2) 165 (132–209) 412 (320–520) 806 (485–974) 1,038
µg/g creatinine  46.1 (39.0–54.4) 5.11 (4.16–5.57) 10.9 (9.29–13.0) 45.6 (34.5–59.7) 170 (142–234) 447 (339–706) 814 (640–995) 1,038
CI, confidence interval.
aParticipants not defined by the three racial/ethnic groups shown were included only in the total population estimate. LOD = 1.0 µg/L.Exposure of the U.S. population to parabens
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available in increments of $5,000 (ranging 
from < $5,000 to > $75,000). We categorized 
income as < $20,000, $20,000–$45,000, 
and > $45,000 to obtain a comparable num-
ber of participants per group. For the mul-
tiple regression models, we used the variables 
described previously and all their possible 
two-way interactions to calculate the adjusted 
least-square geometric mean (LSGM) concen-
trations (micrograms per liter) of MP and PP. 
These variables were log transformed because 
the distributions of concentrations of these 
parabens and creatinine were skewed.
To arrive at the final model, we used 
backward elimination with SUDAAN to 
remove the nonsignificant interactions one at 
a time for each analyte. Nonsignificant main 
effects were then removed one at a time, and 
the model was rerun to determine whether 
the β-coefficients for significant main effects 
or interactions changed by > 10%. If any did, 
we retained the nonsignificant main effect 
in the model. Once the backward procedure 
was completed, main effects and interactions 
were added back into the model one at a time 
to determine whether any were significant 
(p < 0.05). We retained those that were in the 
final model.
We also conducted weighted univariate 
and multiple logistic regressions to examine 
the association of MP and PP concentrations 
above the 95th percentile with sex, age group, 
race/ethnicity, household income, and exami-
nation session.
Results
We detected MP at concentrations ranging 
from 1.0 to 17,300 µg/L in 99.1% of per-
sons examined. We detected PP in 92.7% of 
persons at concentrations of 0.2–7,210 µg/L. 
We detected EP and BP less frequently and 
at lower concentration ranges (EP: 42.4%, 
1.0–1,110 µg/L; BP: 47%, 0.2–1,240 µg/L) 
than MP and PP. The geometric mean and 
95th percentile concentrations were 56.4 µg/L 
(55.0 µg/g creatinine) and 974 µg/L (902 µg/g 
creatinine) for MP, and 7.72 µg/L (7.53 µg/g 
creatinine) and 299 µg/L (263 µg/g creatinine) 
for PP, respectively (Tables 1 and 2). Because 
the weighted frequency of detection was 
< 60% for BP (except for females) and EP, we 
did not calculate the geometric mean (Tables 3 
and 4) or conduct multivariate analysis.
We found that the concentrations of MP 
and PP were highly correlated [Pearson corre-
lation coefficient (R) = 0.62350, p < 0.0001]. 
We also observed significant (p < 0.0001), 
but not as strong (R = 0.49637), correlations 
between the concentrations of BP and EP. The 
correlations between MP or PP and both BP 
and EP were weaker (R = 0.17911–0.34222) 
yet statistically significant (p < 0.0001).
The final MP and PP models included log 
creatinine, income, and the interaction terms 
sex × race/ethnicity (only for PP), sex × age 
(p < 0.01), and age × race/ethnicity (p < 0.01) 
(Table 5). For both parabens, LSGM con-
centrations for persons in the high household 
income category were significantly higher than 
for those in the low (p < 0.01) and medium 
(MP, p = 0.05; PP, p < 0.01) categories 
(Table 5). Females had significantly higher 
concentrations (p < 0.01) of both parabens 
than did males for all age groups, except chil-
dren (MP, p = 0.11; PP, p = 0.81) (Figure 1); 
females also had significantly higher PP con-
centrations (p < 0.01) than did males, regard-
less of race/ethnicity (Table 5). Regardless 
of sex, adults ≥ 60 years of age had signifi-
cantly higher LSGM concentrations of both 
parabens than did children (MP, p = 0.05; 
PP, p < 0.01) and adolescents (p = 0.03). 
Children had significantly lower LSGM con-
centrations than did adults 20–59 years of age 
Table 2. Geometric means and selected percentiles (95% CIs) of PP concentrations in urine for the U.S. population ≥ 6 years of age: NHANES 2005–2006.
Variable Geometric mean
Percentile Sample 
size 10th 25th 50th 75th 90th 95th
All
µg/L 7.91 (6.41–9.77) 0.300 (0.200–0.400) 1.20 (0.900–1.60) 8.70 (5.90–12.4) 48.9 (36.6–64.8) 160 (129–200) 299 (237–354) 2,548
µg/g creatinine 7.71 (6.40–9.30) 0.344 (0.278–0.422) 1.17 (0.896–1.58) 8.27 (5.87–11.3) 52.9 (41.6–66.1) 161 (140–178) 263 (226–288) 2,548
Age group (years)
6–11
µg/L 3.41 (2.43–4.77) 0.300 (< LOD–0.500) 0.800 (0.700–1.20) 2.50 (1.60–4.30) 11.1 (7.10–21.0) 47.5 (30.0–91.9) 125 (55.8–383) 356
µg/g creatinine 3.75 (2.67–5.26) 0.412 (< LOD–0.684) 1.01 (0.682–1.51) 2.70 (1.89–4.43) 11.5 (8.07–16.0) 52.1 (22.9–100) 121 (55.5–352) 356
12–19
µg/L 8.16 (5.70–11.7) 0.400 (< LOD–0.500) 1.50 (0.900–2.60) 8.40 (5.00–13.9) 46.4 (24.1–68.5) 165 (96.7–222) 310 (201–361) 702
µg/g creatinine 6.08 (4.36–8.49) 0.350 (0.223–0.571) 1.23 (0.676–1.82) 5.44 (3.03–10.5) 33.0 (20.7–48.7) 116 (81.9–161) 175 (140–239) 702
20–59
µg/L 8.99 (6.88–11.7) 0.400 (< LOD–0.600) 1.50 (1.10–2.00) 11.3 (7.50–15.3) 52.2 (38.2–75.7) 162 (118–240) 317 (215–370) 1,040
µg/g creatinine 8.63 (6.84–10.9) 0.350 (< LOD–0.473) 1.33 (0.972–1.81) 9.79 (6.57–15.2) 58.1 (42.9–80.4) 178 (144–198) 265 (226–306) 1,040
≥ 60
µg/L 7.67 (6.00–9.80) 0.200 (< LOD–0.400) 0.900 (0.600–1.40) 9.70 (5.70–13.7) 64.5 (39.4–87.6) 190 (134–251) 295 (219–386) 450
µg/g creatinine 8.92 (6.93–11.5) 0.268 (< LOD–0.378) 0.891 (0.571–1.28) 12.9 (8.82–22.7) 77.6 (60.0–106) 177 (142–228) 278 (199–309) 450
Sex
Female
µg/L 20.4 (16.0–25.9) 0.900 (0.700–1.40) 5.30 (3.20–8.30) 29.1 (21.6–37.5) 93.0 (75.7–129) 254 (193–318) 357 (318–395) 1,278
µg/g creatinine 23.9 (19.9–28.8) 1.25 (0.816–1.79) 6.25 (3.73–10.0) 34.9 (26.9–46.6) 114 (101–132) 235 (193–263) 306 (277–342) 1,278
Male
µg/L 2.96 (2.33–3.77) < LOD 0.600 (0.400–0.800) 2.30 (1.60–3.10) 13.8 (9.00–18.0) 51.7 (39.7–70.9) 125 (77.2–185) 1,270
µg/g creatinine 2.38 (1.92–2.95) < LOD 0.513 (0.422–0.654) 1.84 (1.42–2.47) 9.52 (6.79–12.8) 40.4 (31.0–51.5) 90.8 (58.6–125) 1,270
Race/ethnicitya
Mexican American
µg/L 10.6 (8.08–13.8) 0.500 (0.300–0.800) 1.8 (1.10–2.90) 12.1 (7.00–17.5) 65.9 (43.5–93.3) 247 (174–293) 389 (293–453) 637
µg/g creatinine  9.49 (7.29–12.4) 0.449 (0.268–0.690) 1.43 (0.893–2.23) 11.0 (6.69–16.4) 55.2 (44.9–79.6) 186 (147–271) 329 (194–441) 637
Non-Hispanic black
µg/L 26.8 (21.5–33.3) 1.60 (1.30–2.10) 6.60 (4.50–8.60) 34.7 (28.3–44.2) 125 (89.5–165) 331 (236–411) 531 (367–730) 678
µg/g creatinine  18.8 (15.2–23.3) 1.14 (0.822–1.41) 4.75 (3.67–6.57) 23.6 (19.0–30.8) 83.7 (61.8–105) 217 (169–255) 318 (242–377) 678
Non-Hispanic white
µg/L 6.21 (5.02–7.68) 0.300 (< LOD–0.400) 1.00 (0.700–1.30) 6.00 (4.60–9.10) 35.7 (28.4–49.6) 130 (92.1–157) 229 (156–318) 1,038
µg/g creatinine  6.53 (5.32–8.02) 0.286 (< LOD–0.377) 1.01 (0.700–1.36) 6.45 (3.98–9.11) 47.4 (32.6–65.3) 146 (119–184) 241 (184–278) 1,038
CI, confidence interval.
aParticipants not defined by the three racial/ethnic groups shown were included only in the total population estimate. LOD = 0.2 µg/L.Calafat et al.
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(MP, p = 0.03; PP, p < 0.01) and adolescents 
(p = 0.04 for PP only) (Table 5, Figure 1). 
Except for persons ≥ 60 years of age, LSGM 
concentrations of MP were significantly 
higher for non-Hispanic blacks than for 
non-Hispanic whites (p < 0.01; Table 5, 
Figure 2). Similarly, non-Hispanic black 
children and adolescents (p < 0.01) had sig-
nificantly higher concentrations of MP than 
Mexican Americans. We found the same pat-
tern for PP (Table 5), except that the differ-
ences for adolescents were only of borderline 
significance (p = 0.07). Mexican Americans 
had higher LSGM concentrations of both 
MP and PP than did non-Hispanic whites 
(Table 5), but the differences reached statisti-
cal significance (p < 0.01) only among adults 
and adolescents for MP. Among Mexican 
Americans, adults had significantly higher 
LSGM concentrations (p < 0.01) of both MP 
and PP than did children and adolescents; the 
LSGM concentrations among children were 
significantly lower than those for adults ≥ 60 
years of age (p < 0.01) and adolescents (MP, 
p = 0.01; PP, p < 0.01). Among non-Hispanic 
whites, adults and older adults had signifi-
cantly higher LSGM concentrations than did 
adolescents (MP, p < 0.01; PP, p = 0.03 for 
adults and p < 0.01 for older adults) and chil-
dren (p < 0.01) (Table 5). Among non-His-
panic blacks, adults had significantly higher 
LSGM concentrations of MP and PP than 
did children (MP, p = 0.02; PP, p < 0.01), 
and adolescents also had significantly higher 
LSGM concentrations of PP than did chil-
dren (p = 0.01) (Table 5).
For both MP and PP, the likelihood of 
having a urinary concentration above the 
95th percentile (an arbitrary value selected 
as an example of higher than average con-
centrations) was significantly associated with 
sex (p < 0.01) and race (p < 0.01) but not 
with age, income, or examination session. 
Females were about three to four times more 
likely than males to have urinary concentra-
tions of MP and PP above the 95th percen-
tile [adjusted odds ratios (ORs) with 95% 
confidence intervals (CIs): MP, 3.2 (2.99–
5.27); PP, 4.19 (2.34–7.49)]. Compared with 
non-Hispanic whites, the likelihood of hav-
ing urinary concentrations of MP or PP at 
or above the 95th percentile was two to five 
times higher for non-Hispanic blacks [MP, 
4.99 (2.62–9.50); PP, 3.6 (1.86–7.05)] and 
for Mexican Americans (MP, 2.03 (1.30–
3.17); PP, 2.56 (1.56–4.24)]. Non-Hispanic 
blacks were about 2.5 times more likely than 
Mexican Americans to have MP concentra-
tions above the 95th percentile [2.45 (1.41–
4.28)], but we found no significant difference 
(p = 0.13) between non-Hispanic blacks and 
Mexican Americans for PP.
Discussion
We detected concentrations of free plus 
conjugated species of MP and PP in urine 
in > 92% of the samples examined; we 
detected EP and BP in about 50%. The high 
frequency of detection of MP and PP most 
likely resulted from their wide use in food 
products (Soni et al. 2005) and in common 
personal care products (e.g., lotions, cosmet-
ics, hair preparations) (Andersen 2008). The 
range of urinary concentrations spanning up 
to three orders of magnitude (Tables 1–4) 
may be related to lifestyle factors, includ-
ing diet, that result in exposure differences 
and/or to individual variations in bioavail-
ability, distribution kinetics, or metabolism 
of the parabens. These factors are important 
in interpreting biomonitoring data for other 
chemicals found in personal care products, 
such as the bactericide triclosan (Calafat et al. 
2008b; Sandborgh-Englund et al. 2006) 
Table 3. Geometric mean and selected percentiles (95% CIs) of BP concentrations in urine for the U.S. population ≥ 6 years of age: data from NHANES 2005–2006.
Variable Geometric mean
Percentile Sample 
size 10th 25th 50th 75th 90th 95th
All
µg/L — < LOD < LOD  < LOD 1.30 (0.800–1.80) 6.60 (4.80–10.7) 19.6 (16.4–26.7) 2,548
µg/g creatinine — < LOD < LOD  < LOD 1.16 (0.909–1.62) 7.82 (6.26–11.2) 21.2 (16.8–27.3) 2,548
Age group (years)
6–11
µg/L — < LOD < LOD  < LOD 0.400 (0.200–0.600) 1.90 (0.800–5.80) 7.50 (1.70–18.5) 356
µg/g creatinine — < LOD < LOD  < LOD 0.442 (0.368–0.663) 1.65 (1.00–5.29) 7.92 (1.64–30.5) 356
12–19
µg/L — < LOD < LOD 0.200 (< LOD–0.400) 0.0900 (0.600–1.80) 9.60 (4.10–16.1) 24.6 (14.5–33.4) 702
µg/g creatinine — < LOD < LOD 0.194 (< LOD–0.255) 0.0694 (0.486–1.20) 6.67 (3.60–11.2) 18.7 (9.52–28.9) 702
20–59
µg/L — < LOD < LOD  < LOD 1.80 (0.900–2.50) 6.50 (4.30–11.7) 17.8 (10.1–28.2) 1,040
µg/g creatinine — < LOD < LOD  < LOD 1.48 (1.01–1.97) 7.81 (5.36–13.6) 19.8 (13.0–26.9) 1,040
≥ 60
µg/L — < LOD < LOD  < LOD 1.10 (0.400–2.20) 11.8 (5.00–23.5) 41.6 (16.5–92.0) 450
µg/g creatinine — < LOD < LOD  < LOD 1.49 (0.824–2.59) 18.2 (6.05–39.2) 52.8 (20.9–74.4) 450
Sex
Female
µg/L 0.904 (0.760–1.07) < LOD < LOD 0.500 (0.400–0.700) 3.70 (2.90–4.80) 17.4 (11.7–20.8) 34.9 (28.2–41.1) 1,278
µg/g creatinine 1.06 (0.914–1.24) < LOD < LOD 0.750 (0.598–0.857) 4.44 (3.01–6.26) 19.8 (13.5–25.7) 34.7 (26.9–42.7) 1,278
Male
µg/L — < LOD < LOD  < LOD 0.300 (< LOD–0.300) 1.10 (0.600–2.00) 3.20 (1.90–5.50) 1,270
µg/g creatinine — < LOD < LOD  < LOD 0.292 (< LOD–0.349) 0.0833 (0.565–1.16) 2.28 (1.43–2.91) 1,270
Race/ethnicitya
Mexican American
µg/L — < LOD < LOD 0.200 (< LOD–0.300) 1.10 (0.700–2.30) 11.3 (6.40–15.6) 27.3 (16.5–35.9) 637
µg/g creatinine  — < LOD < LOD 0.240 (< LOD–0.294) 1.21 (0.761–1.68) 9.16 (5.36–15.2) 20.3 (15.8–29.2) 637
Non-Hispanic black
µg/L — < LOD < LOD 0.300 (0.200–0.400) 2.10 (1.00–3.50) 9.10 (4.40–25.0) 31.8 (10.1–82.6) 678
µg/g creatinine  — < LOD < LOD 0.217 (< LOD–0.272) 1.46 (0.746–2.64) 8.18 (3.65–17.9) 21.0 (10.8–51.3) 678
Non-Hispanic white
µg/L — < LOD < LOD  < LOD 1.00 (0.700–1.80) 5.80 (4.00–9.00) 17.7 (11.7–25.9) 1,038
µg/g creatinine  — < LOD < LOD  < LOD 1.12 (0.847–1.65) 6.93 (5.21–9.91) 20.9 (15.4–27.3) 1,038
CI, confidence interval. —, not calculated: proportion of results below the LOD was too high to provide a valid result. 
aParticipants not defined by the three racial/ethnic groups shown were included only in the total population estimate. LOD = 0.2 µg/L.Exposure of the U.S. population to parabens
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and the sunscreen agent benzophenone-3 
(Calafat et al. 2008a). All these factors as well 
as the timing of sample collection will affect 
the urinary concentrations of parabens on 
an individual basis. On a population basis 
(e.g., NHANES), however, the wide range 
of concentrations observed would represent 
an average exposure scenario (i.e., a paraben 
urinary concentration in the upper percen-
tiles resulting from the collection of the urine 
soon after a person’s paraben-related activity 
may be offset by a concentration in the lower 
percentiles of another person who provided 
a urine sample shortly before conducting the 
same activity).
We observed moderate correlations 
between the concentrations of EP and BP, 
and much weaker correlations between either 
of these parabens and MP or PP. These find-
ings suggest a potential common source(s) 
of exposure for EP and BP, which was not 
the case for MP and PP. The concentrations 
of MP and PP were highly correlated, most 
likely because they are the two most common 
parabens (Soni et al. 2005) and may be used 
in combination in many commercial applica-
tions, including food, pharmaceuticals, and 
personal care products.
We previously reported the urinary con-
centrations of free plus conjugated species 
of several parabens in a convenience sample 
of 100 adults during 2003–2005 (Ye et al. 
2006a). The frequencies of detection were 
comparable among the sample (MP, 99%; 
PP, 96%; EP, 58%; BP, 69%) and NHANES 
2005–2006 (MP, 99.1%; PP, 92.7%; EP, 
42%; BP, 47%). In addition, the median 
concentrations were practically the same for 
PP, slightly higher for MP, and lower for BP 
and EP in the NHANES 2005–2006 sample 
compared with the convenience population. 
Although exposure to these parabens (assessed 
by the urinary concentrations) may have 
changed, these two data sets are not directly 
comparable for establishing temporal expo-
sure trends because of the small sample size 
and lack of national representativeness of the 
convenience sample. Nonetheless, both data 
sets confirm considerable human exposure 
to parabens and could potentially be used 
to derive internal dose exposure estimates. 
Of interest, the convenience biomonitoring 
samples have already been used to estimate 
internal dose of parabens (Cowan-Ellsberry 
and Robison 2009). Unfortunately, data 
are lacking regarding human metabolism of 
parabens, particularly of the fraction of the 
paraben excreted in the urine as the parent 
paraben (free or conjugated) versus the frac-
tion excreted as p-hydroxybenzoic acid. This 
information, including a better understanding 
of the possible differences in metabolism by 
exposure route in humans, is needed to ade-
quately link paraben urinary biomarker mea-
surements to exposure and to internal dose.
We report here for the first time the con-
centrations of parabens among children and 
adolescents. Our data confirm that exposure 
occurs at these younger ages. Further, the 
apparent lower exposure among the younger 
segments of this NHANES 2005–2006 pop-
ulation (reflected in lower urinary concen-
trations than for adults) is likely associated 
with lifestyle. For example, in general, adults 
are more likely to use pharmaceuticals and 
personal care products than are children. We 
observed a similar age pattern for monoethyl 
phthalate (Silva et al. 2004), a metabolite of 
diethyl phthalate (DEP) for which a primary 
source of exposure may be the routine use of 
personal care products (Duty et al. 2005).
Although parabens are nonpersistent chem-
icals that are excreted from the body within 
hours after exposure (Janjua et al. 2008), 
Table 4. Selected percentiles (95% CIs) of EP concentrations in urine for the U.S. population ≥ 6 years of age: data from NHANES 2005–2006.
Variable
Percentile Sample 
size 10th 25th 50th 75th 90th 95th
All
µg/L < LOD < LOD < LOD 4.80 (3.40–6.00) 26.2 (19.4–31.9) 57.2 (40.3–83.4) 2,548
µg/g creatinine < LOD < LOD < LOD 4.61 (3.39–6.30) 27.1 (19.1–34.0) 66.5 (46.5–84.2) 2,548
Age group (years)
6–11
µg/L < LOD < LOD < LOD < LOD 2.60 (1.70–4.70) 9.90 (2.80–30.7) 356
µg/g creatinine < LOD < LOD < LOD < LOD 4.18 (1.91–10.2) 13.4 (4.18–29.0) 356
12–19
µg/L < LOD < LOD < LOD 2.30 (1.30–3.20) 11.3 (7.90–24.1) 38.0 (17.7–122) 702
µg/g creatinine < LOD < LOD < LOD 1.94 (1.29–2.65) 10.9 (3.57–20.1) 32.0 (14.1–57.8) 702
20–59
µg/L < LOD < LOD < LOD 6.00 (4.80–8.10) 29.1 (20.7–37.4) 62.8 (42.4–86.8) 1,040
µg/g creatinine < LOD < LOD < LOD 5.83 (4.63–7.58) 27.5 (18.2–38.2) 70.0 (46.0–91.2) 1,040
≥ 60
µg/L < LOD < LOD < LOD 5.90 (3.00–12.0) 32.0 (18.9–54.7) 76.4 (32.9–136) 450
µg/g creatinine < LOD < LOD < LOD 7.32 (4.56–11.6) 57.0 (27.5–78.9) 83.4 (50.0–135) 450
Sex
Female
µg/L < LOD < LOD 1.30 (< LOD–2.20) 10.0 (7.50–13.2) 42.7 (32.3–62.8) 98.7 (74.7–147) 1,278
µg/g creatinine < LOD < LOD 2.09 (< LOD–2.60) 12.7 (8.45–16.2) 57.3 (40.7–75.2) 107 (82.9–141) 1,278
Male
µg/L < LOD < LOD < LOD 1.90 (1.10–3.00) 8.90 (5.80–13.6) 25.2 (16.0–29.2) 1,270
µg/g creatinine < LOD < LOD < LOD 1.82 (1.48–2.15) 6.38 (3.55–9.95) 15.5 (10.2–22.3) 1,270
Race/ethnicitya
Mexican American
µg/L < LOD < LOD < LOD 3.70 (1.90–6.10) 24.0 (11.6–37.7) 55.6 (40.3–120) 637
µg/g creatinine  < LOD < LOD < LOD 3.49 (2.09–5.23) 23.5 (11.8–33.2) 68.5 (32.1–107) 637
Non-Hispanic black
µg/L < LOD < LOD 1.00 (< LOD–1.50) 5.70 (3.70–9.80) 31.3 (20.4–52.1) 92.3 (41.5–166) 678
µg/g creatinine  < LOD < LOD 0.972 (< LOD–1.14) 4.48 (2.90–6.07) 22.0 (14.1–36.8) 47.5 (33.7–106) 678
Non-Hispanic white
µg/L < LOD < LOD < LOD 4.80 (3.10–6.10) 24.0 (15.5–32.3) 54.7 (36.4–86.8) 1,038
µg/g creatinine  < LOD < LOD < LOD 4.73 (3.38–6.58) 27.5 (16.2–38.4) 70.6 (46.0–91.2) 1,038
CI, confidence interval. Geometric means for EP were not calculated: the proportion of results below the LOD was too high to provide a valid result.
aParticipants not defined by the three racial/ethnic groups shown were included only in the total population estimate. LOD = 1.0 µg/L.Calafat et al.
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examination session used as a surrogate for the 
time of urine collection was not a significant 
factor in explaining the variance of the urinary 
concentrations of the parabens. In contrast, 
we observed important differences in concen-
trations on the basis of demographic charac-
teristics. Specifically, the LSGM MP and PP 
concentrations were significantly greater among 
people in the high household income category 
than among those in the medium- and low-
income categories (Table 5), suggesting that 
the use of pharmaceuticals and personal care 
products according to socioeconomic status 
may affect paraben exposure.
Of interest, we observed that LSGM 
concentrations of MP and PP were highly 
dependent upon sex, age, and race/ethnic-
ity (Table 5, Figures 1 and 2), as we have 
reported for other compounds (or their 
metabolites) found in personal care products, 
such as DEP (Silva et al. 2004) and benzo-
phenone-3 (Calafat et al. 2008a). The higher 
concentrations of MP and PP found among 
women than among men were likely attrib-
utable to women’s increased use of personal 
care products, such as cosmetics and lotions. 
Non-Hispanic black children and adolescents 
had LSGM concentrations of MP and PP that 
were higher than or very similar to the con-
centrations in non-Hispanic black adults; non-
Hispanic blacks had much higher MP and PP 
concentrations than did the other two race/
ethnicity groups, particularly among children, 
adolescents, and adults 20–59 years old. These 
differences may result from increased, con-
tinuous, or prolonged use of beauty, hair, and/
or skin care products specifically marketed to 
this population in whom the use often begins 
at a young age. The less dramatic differences 
by race/ethnicity among older adults may be 
explained by increased use of pharmaceuticals 
regardless of race/ethnicity that may compen-
sate for differences in personal care products 
use. Because MP and PP are also used in food 
products, we cannot rule out that potential 
differences in diet, should they exist, may have 
also contributed to the differences in urinary 
concentrations of MP and PP among the vari-
ous demographic groups examined.
Identifying populations in the highest 
exposure category (i.e., with concentrations 
above the 95th percentile) is an important 
consideration for public health. Our data sug-
gest that females, non-Hispanic blacks, and, 
to a lesser extent, Mexican Americans have 
higher exposures to MP and PP than do other 
demographic segments of the general popula-
tion. Specifically, females and non-Hispanic 
blacks were more likely to exhibit concentra-
tions of MP and PP above the 95th percen-
tile than were males, non-Hispanic whites, 
or Mexican Americans. In particular, females 
were 3.2 times more likely than males, and 
non-Hispanic blacks were about 5 times more 
likely than non-Hispanic whites and 2.5 times 
more likely than Mexican Americans, to have 
MP concentrations above the 95th percentile. 
Mexican Americans were about twice as likely 
as non-Hispanic whites to present MP concen-
trations above the 95th percentile. Similarly, 
for PP, females were 4.2 times more likely than 
males, and non-Hispanic whites were 3.6 times 
less likely than non-Hispanic blacks and 2.56 
times less likely than Mexican Americans, to 
have MP concentrations above the 95th per-
centile. The likelihood of presenting PP con-
centrations above the 95th percentile did not 
differ (p = 0.13) between Mexican Americans 
and non-Hispanic blacks. Age was not signifi-
cantly associated with having concentrations 
above the 95th percentile for either MP or PP.
In summary, we found significant differ-
ences in concentrations of parabens across 
demographic groups, particularly those associ-
ated with sex and race/ethnicity. These data 
can be used to establish a nationally repre-
sentative baseline assessment of exposure—a 
baseline against which the concentrations of 
these parabens in future populations can be 
compared in order to identify exposure trends. 
These NHANES 2005–2006 data may also be 
useful in a risk assessment of parabens if war-
ranted by toxicologic or epidemiologic studies.
Figure 1. LSGM urinary concentrations by age and sex: (A) MP; (B) PP. Error bars indicate 95% CIs.
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Figure 2. LSGM urinary concentrations by age and race/ethnicity: (A) MP; (B) PP. Error bars indicate 95% CIs.
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Table 5. Adjusted LSGM concentrations (95% CIs) 
of MP and PP in various demographic groups.
LSGM [µg/L (95% CI)]
  MP PP
Household income
< $20,000 48.6 (40.8–57.9) 6.2 (5.3–7.4)
$20,000–$45,000  49.3 (41.4–58.7) 7.0 (5.6–8.7)
> $45,000 62.1 (52.7–73.1) 9.1 (7.7–10.8)
Sex × race/ethnicity
Male
Mexican American 4.3 (3.6–5.3)
Non-Hispanic white 1.9 (1.5–2.3)
Non-Hispanic black 8.9 (6.5–12.2)
Female
Mexican American 33.6 (27.2–41.6)
Non-Hispanic white 21.1 (16–27.8)
Non-Hispanic black 45.2 (35.8–57.1)
Sex × age
Male
6–11 years 26 (15.9–42.3) 2.6 (1.5–4.4)
12–19 years 20.8 (17.2–25.2) 2.2 (1.6–3.0)
20–59 years 24 (19.5–29.5) 2.5 (1.9–3.3)
≥ 60 years 30 (21–42.9) 2.7 (1.6–4.5)
Female
6–11 years 46.5 (30.7–70.3) 4.5 (2.8–7.2)
12–19 years 74.1 (60.6–90.7) 18.2 (13.2–25.2)
20–59 years 144.6 (113.6–184.1) 31.6 (24.3–41.1)
≥ 60 years 160.2 (129.6–198.1) 28.8 (22.3–37.3)
Race/ethnicity × age
Mexican American
6–11 years 39 (27.6–54.9) 3.9 (2.8–5.3)
12–19 years 71 (59.2–85.2) 8.6 (6.6–11.4)
20–59 years 102.7 (84.5–124.7) 16.9 (13.4–21.3)
≥ 60 years 90.4 (59.4–137.5) 8.7 (5.0–15)
Non-Hispanic white
6–11 years 26.9 (19.4–37.3) 2.4 (1.6–3.6)
12–19 years 28.7 (24.1–34.2) 4.8 (3.4–6.8)
20–59 years 47.7 (38.8–58.6) 7 (5.4–9.1)
≥ 60 years 63.5 (49.3–81.9) 8.3 (6.0–11.6)
Non-Hispanic black
6–11 years 138.7 (92.7–207.7) 20.3 (14.2–29)
12–19 years 154.5 (116.3–205.2) 23.8 (16.3–34.6)
20–59 years 133.6 (96.7–184.6) 22.3 (16.4–30.5)
≥ 60 years 95.7 (64.3–142.4) 12.5 (7.9–19.8)Exposure of the U.S. population to parabens
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